文献速递白血病造血干细胞移植与细胞治疗

维奈克拉联合地西他滨作为老年急性髓系白血病患者异基因造血干细胞移植桥接治疗(VEN-DEC GITMO):多中心、单臂、2期试验最终报告

Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2024-09-20

这项在意大利20个GITMO中心开展的多中心单臂2期试验纳入93例≥60岁且<75岁、适合移植的新诊断中高危急性髓系白血病患者,评估维奈克拉联合地西他滨一线诱导并桥接异基因造血干细胞移植的疗效。结果显示64例(69%)达完全缓解,53例(57%)在完全缓解期接受移植,完全缓解者中53/64(83%)接受移植;≥3级不良事件发生于49例(53%),未观察到治疗相关死亡。

要点

  • 维奈克拉联合地西他滨诱导后69%(64/93)达完全缓解,57%(53/93)在完全缓解期接受移植。
  • 完全缓解患者中83%(53/64)成功桥接移植,5例(8%)移植前复发、其中4例死亡。
  • ≥3级不良事件见于53%(49/93),最常见为感染(28/49,57%),其中7例死亡。

核心结论

  • 维奈克拉联合地西他滨诱导可显著提高被认为适合移植的老年急性髓系白血病患者接受异基因造血干细胞移植的可行性。

研究设计与样本

  • 多中心、单臂、2期试验,在意大利20个GITMO中心开展,纳入93例年龄≥60且<75岁、新诊断中高危急性髓系白血病、ECOG体力状态<2且被认为适合异基因造血干细胞移植的患者。
  • 维奈克拉口服3天剂量递增:第1天100 mg、第2天200 mg、第3天起400 mg每日一次,每28天为一周期,共2至4周期;地西他滨20 mg/m2静脉给药,每28天第1至5天。
  • 主要终点为所有接受至少一剂研究药物的患者中,在首次完全缓解期间接受异基因造血干细胞移植的比例。

主要发现

  • 2021年6月1日至2022年12月30日共入组93例并开始维奈克拉联合地西他滨诱导,其中中危44例(47%)、高危49例(53%)。
  • 中位年龄68.5岁(IQR 60.3-74.7),93例均为白人,女性43例(46%)、男性50例(54%),中位随访236天(IQR 121-506)。
  • 93例中64例(69%)达完全缓解,53例(57%)在完全缓解期接受异基因造血干细胞移植;64例完全缓解者中53例(83%)接受移植。
  • 64例完全缓解者中5例(8%)移植前复发,其中4例因此死亡。
  • ≥3级不良事件发生于49/93例(53%),最常见为感染(包括肺炎、细菌性脓毒症和SARS-CoV-2,发生于28/49例[57%],导致7例死亡)、中性粒细胞减少17例(35%)、血小板减少2例(4%,包括1例致死性中枢神经系统出血)和心脏事件4例(8%,包括1例致死性心力衰竭);未观察到治疗相关死亡。

临床怎么用

  • 作者认为,维奈克拉联合地西他滨诱导可显著提高被认为适合移植的老年急性髓系白血病患者接受异基因造血干细胞移植的可行性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Access to allogeneic haematopoietic stem-cell transplantation (HSCT) remains challenging for older patients (aged >60 years) with acute myeloid leukaemia. We aimed to evaluate the efficacy of venetoclax plus decitabine as first-line therapy and bridge to transplantation in this patient population. METHODS: This multicentre, single-arm, phase 2 trial was conducted in 20 Gruppo Italiano Trapianto Midollo Osseo (GITMO) centres in Italy. Patients aged ≥60 and <75 years, with newly diagnosed acute myeloid leukaemia categorised as intermediate or high risk according to 2016 WHO and 2017 European LeukemiaNet, an ECOG performance status of less than 2, and considered fit for allogeneic HSCT were included. Patients received oral venetoclax with a 3-day ramp-up: 100 mg on day 1, 200 mg on day 2, and 400 mg once per day from day 3 of cycle one, and then every 28 days of each cycle (two to four in total). Decitabine was administered intravenously at a dose of 20 mg/m2 from days 1 to 5 every 28 days. At cycle one, patients were admitted to hospital for a minimum of 24 h, whereas subsequent cycles could be administered on an outpatient basis. Two additional cycles were allowed while waiting for allogeneic HSCT or for those with no response or partial response after cycle two. The primary endpoint was the proportion of patients who had allogeneic HSCT performed during first complete remission, assessed in all patients who received at least one dose of the study medication. This study was registered with ClinicalTrials.gov (NCT04476199, ongoing) and EudraCT (2020-002297-26). FINDINGS: Between June 1, 2021, and Dec 30, 2022, 93 patients were enrolled and started venetoclax plus decitabine induction (44 [47%] at intermediate risk and 49 [53%] at high risk). The median age was 68·5 (IQR 60·3-74·7). All 93 participants were White, of whom 43 (46%) were female and 50 (54%) were male. The median follow-up was 236 days (IQR 121-506). 64 (69%) of 93 patients reached complete remission and 53 (57%) underwent allogeneic HSCT in complete remission. 53 (83%) of 64 with a complete remission underwent allogeneic HSCT. Five (8%) of 64 patients in complete remission relapsed before transplantation and four died as a consequence. Adverse events (grade ≥3) occurred in 49 (53%) of 93 patients. The most common adverse events were infections (including pneumonia, bacterial sepsis, and SARS-CoV-2 causing seven deaths among 28 [57%] of 49 patients), neutropenia (17 [35%]), thrombocytopenia (two [4%], including one fatal CNS bleeding), and cardiac events (four [8%], including one fatal heart failure). No treatment-related deaths were observed. INTERPRETATION: Venetoclax plus decitabine induction can significantly enhance the feasibility of allogeneic HSCT in older patients with acute myeloid leukaemia who are deemed fit for transplantation. FUNDING: AbbVie and Johnson & Johnson.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Russo D, Polverelli N, Bernardi S, et al. Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2024. PMID: 39312920. doi:10.1016/S2352-3026(24)00241-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。